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ABSTRACT 
Introduction: Troponin release is common during critical illness. We hypothesized that there was an 
association between cardiac troponin T (cTnT) and biomarkers of systemic inflammation and ventricular 
dilatation.  
Methods: In an observational prospective cohort study, we enrolled consecutive adult patients admitted 
for non-cardiac reasons to the Intensive Care Unit (ICU) in 2 tertiary care centers. We measured cTnT, C-
reactive protein (CRP), Interleukin-6 (IL-6), procalcitonin (PCT) and N-terminal pro brain natriuretic 
peptide (NT-proBNP) daily in the first week, and on alternate days in the second week. Using a peak 
cTnT cut-off ≥15ng/L and concomitant changes on electrocardiogram (ECG), patients were categorised 
as “definite myocardial infarction (MI)”, “possible MI”, “cTnT rise only” or “no cTnT rise”. Within each 
group, associations between CRP, IL-6, PCT, NT-proBNP and cTnT were investigated using mixed effect 
models.  
Results: 172 patients were included in the analysis of whom 84% had a cTnT rise ≥15ng/L. 21 patients 
(12%) had a definite MI, 51 (30%) had a possible MI and 73 (42%) had a cTnT rise only. At time of peak 
cTnT, 71% of patients were septic and 67% were on vasopressors.  
Multivariable analysis showed a significant association between cTnT and IL-6 in all patients with a 
cTnT rise independent of age, gender, renal function and cardiovascular risk factors. In patients without a 
definite MI, cTnT levels were significantly associated with PCT and NT-proBNP values. In patients 
without elevated cTnT levels, there was no associated NT-proBNP rise.  
Conclusions: In ICU patients admitted for non-cardiac reasons, serial cTnT levels were independently 
associated with markers of systemic inflammation and NT-proBNP.  
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INTRODUCTION  
Troponin release is common during critical illness and associated with increased morbidity, mortality and 
length of stay (1-15). We previously showed that 84% of patients admitted to the Intensive Care Unit 
(ICU) for non-cardiac reasons had at least one elevated cardiac troponin T (cTnT) result (10). Only 14% 
of patients fulfilled criteria for a definite myocardial infarction (MI), and 27% had changes on 
electrocardiogram (ECG) suggestive of a possible MI.  
 
Troponin T is a cardiac-specific molecule that is released into the systemic circulation following 
myocardial cell injury. Sepsis and inflammation are the leading non-cardiac causes of elevated troponin 
levels during critical illness (2, 14, 16-19). In sepsis, the heart undergoes physiologic and metabolic 
changes, including altered coronary blood flow, reduced oxygen extraction, regional and global wall 
hypokinesia and ventricular dilatation (20-23). Coronary blood flow is often increased. In this situation, a 
potential explanation for troponin release is cellular ischaemia due to microcirculatory changes within the 
myocardium (23-25). Circulating inflammatory cytokines appear to contribute through direct 
myocytotoxic effects, perturbations in microvascular flow and effects on cell permeability (20, 26). 
Regional and global wall hypokinesia resulting in increased cardiac filling pressures and ventricular 
dilatation may also play a role. 
 
We hypothesized that there was a relationship between cTnT levels and biomarkers of systemic 
inflammation and ventricular dilatation during critical illness.  
 
MATERIALS AND METHODS 
Objectives  
Our objectives were:  
i) to investigate the association between cTnT and C-reactive protein (CRP), Interleukin-6 (IL-6), and 
procalcitonin (PCT) as markers of systemic inflammation;   
ii) to investigate the association between cTnT and N-Terminal pro brain natriuretic peptide (NT-proBNP) 
as a biomarker of ventricular dilatation.  
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Study protocol  
The study protocol and methods have been described in detail elsewhere (10). We included a second centre 
(St George’s University Hospital, London, UK) where the study was conducted during the same time period 
(June 2010 – April 2012) using the same protocol.  
As previously described (10), we enrolled consecutive adult patients (≥18 years) admitted to the ICU for 
non-cardiac reasons. Patients with a high probability of cardiac injury or a primary cardiac diagnosis were 
excluded. In the first week, we measured cTnT, NT-proBNP, CRP, IL-6 and PCT and performed an ECG 
on a daily basis. During the second week, the blood tests and ECGs were taken on alternate days until 
discharge from ICU, death or day 14 after admission, whichever occurred first. Blood samples taken for 
research purposes were stored at -700C and ECGs were kept in secure lockers until batch analysis at the 
end of the study. Clinicians were allowed to order ECGs, cTnT and inflammatory markers separately as 
clinically indicated.  
 
Laboratory analyses 
All laboratory analyses were performed in the Department of Biochemistry at St George’s University 
Hospital by 2 biochemists (ET and PC) who were blinded to the study and not involved in patient 
selection, data collection and data analysis.  
 
Cardiac Troponin T (cTnT) was measured using the Roche electrochemiluminescent high sensitivity 
sandwich immunoassay on the Elecsys 2010 [quoted analytical range: 3-10,000ng/L; total coefficients of 
variation (CVs): 1.5-3.4% (measured between 24-2665ng/L) and reference range: <15ng/L (99th 
percentile)]. NT-proBNP was measured using the Diagnostic Products Corporation (DPC) Immulite 2500 
chemiluminescent sandwich immunoassay [analytical range: 20–35,000pg/ml; quoted total CVs: 3.4–
5.6% (measured between 40.9–32,096pg/ml) and reference range: <125pg/ml in patients <75 years and 
<450pg/ml in those over 75]. PCT was measured using a three-site sandwich immunoassay on the Advia 
Centaur (analytical range: 0.02–75ng/ml and reference range: <0.1ng/ml). CRP was measured using a 
latex enhanced immunoturbidimetric method on the Siemens Advia 2400 [analytical range: 4–336mg/L; 
total CVs: 1.1–1.4% (measured between 32–222mg/L) and reference range: <10mg/L]. IL-6 was 
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measured using the DPC Immulite 2500 chemiluminescent sandwich immunoassay [analytical range: 2–
1000pg/ml; total CVs: 4.6–7.2% (measured between 89–724pg/ml) and reference range: <5.9pg/ml].  
 
Data collection 
We collected demographics, admission diagnosis, cardiovascular risk factors [ischaemic heart disease 
(IHD), diabetes, hypertension, any type of vascular disease], Acute Physiology and Chronic Health 
Evaluation (APACHE) II score, serum creatinine, vasopressor use, treatment with renal replacement 
therapy (RRT), presence of sepsis [as per previous consensus criteria (27)] and ICU and hospital outcome. 
 
Interpretation of troponin levels  
As described previously (10), the ECGs were analysed independently by two senior cardiologists who 
were blinded to the cTnT results and clinical details. In case of discrepancy, adjudication was undertaken 
by a third senior cardiologist. The diagnosis of acute MI was based on the most recent consensus criteria 
(28). Accordingly, patients were classified into four groups depending on their peak cTnT level and ECG 
taken on the same day or the day before: (i) “definite MI”, with cTnT ≥15ng/L and ECG changes 
consistent with MI, (ii) “possible MI”, with cTnT ≥15ng/L and ischaemic changes on ECG but not 
fulfilling criteria for definite MI, (iii) “cTnT rise alone”, and (iv) “no cTnT rise” with peak cTnT <15ng/L. 
 
Statistics 
We used means for continuous variables and proportions for categorical variables to describe baseline 
characteristics. The 4 groups were compared using the Kruskal-Wallis method for continuous variables 
where the distribution was not normal and Chi squared test for categorical variables. The associations 
between cTnT and CRP, IL-6, PCT and NT-proBNP were investigated using two-level mixed effect 
models to take into account the serial measurements over the duration of stay in ICU. The patient 
identifiers were modelled as a random effect and the repeated blood values were effectively averaged 
within patients.  
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The models were initially fitted separately for each predictor to evaluate the unifactorial relationship with 
the outcome cTnT. Multivariable mixed effects models were used to adjust for potential confounders 
including age, gender and history of IHD, hypertension and diabetes or any form of vascular disease. We 
adjusted for renal function by adding a binary covariate indicating ‘treatment with RRT or serum 
creatinine ≥140μmol/L’, versus ‘no RRT and serum creatinine <140μmol/L’. All variables included in the 
models were chosen a priori on clinical grounds and all chosen variables were included in the 
multivariable models. 
 
Since cTnT was log-transformed to correct for positive skewness, the model results were back-
transformed and presented as percentage change associated with a ‘one unit’ change in the variable of 
interest. In order to make it easier to compare the results for different biomarkers, we presented a 
standardised measure of effect by calculating the percentage change in cTnT that would occur if the 
biomarker changed by one standard deviation (SD) of its distribution (29). It was necessary to log-
transform IL-6. As a result, its results could not be expressed in a meaningful way in terms of a 
percentage associated with a unit change. Instead we calculated the change in cTnT for a SD change in 
IL-6 using the SD of the log-transformed data. All results are presented as estimates with 95% confidence 
intervals (CI) wherever possible. To illustrate the variations of each biomarker over time in each of the 4 
groups, the daily median values of CRP, IL-6, PCT, NT-proBNP and cTnT in their original units were 
graphically displayed.  
 
The 4 groups were analysed as independent cohorts as we aimed to examine the differences between the 
characteristics of these, and the associations between the outcome cTnT and the different markers for 
each of the 4 groups. The model residuals were examined for normality using Quantile Quantile (QQ) 
Plots. Stata version 14 was used for the analyses.  
 
Ethics 
The study was approved by a formal Research Ethics Committee (REC) and the Research & 
Development Department in our hospital. Written informed consent was obtained from the patients prior 
Copyright © 2016 by the Shock Society. Unauthorized reproduction of this article is prohibited.
to enrolment. As previously described, if a patient did not have capacity to consent, the opinion of a 
personal consultee was sought in accordance with section 32 of the Mental Capacity Act 2005 (UK). In 
this case, the patients were asked to give informed consent after they had regained capacity. If consent 
was declined, all collected samples and ECGs were discarded. In case retrospective consent could not be 
obtained due to death or lack of capacity, the REC approved that these patients could be included in the 
analysis.  
 
RESULTS 
 Patient population 
We enrolled 179 patients of whom 7 were excluded (5 patients had an acute coronary syndrome on 
admission to ICU which was not recognised by the research team at enrolment and 2 patients were 
transferred to another hospital within 48 hours of ICU admission). The baseline characteristics of the 
remaining 172 patients are shown in Table 1. The main reasons for admission to ICU were sepsis (37%), 
post-emergency surgery (21%), respiratory failure (11%), neurological emergency, including drug overdose 
(10%), gastrointestinal bleed (7%), acute kidney injury (4%) and other non-cardiac causes (10%). 
 
Prevalence of troponin rise  
145 patients (84%) had at least one cTnT value ≥15ng/L during their stay in ICU. Among them, 21 (12%) 
had contemporaneous ECG changes consistent with a definite MI of whom 14 were recognised by the 
clinical team and 4 underwent coronary angiography. Fifty-one patients (35%) had ECG changes 
suggestive of a possible MI and 73 (42%) had a cTnT rise without any ECG changes. 27 patients (16%) 
had no cTnT rise ≥15ng/L. The mean, median, ranges (minimum – maximum) and interquartile ranges 
(IQR) of the cTnT levels are shown in Table 2. Between 1–11 daily measurements were taken per patient, 
and estimates were based on repeated measures over the observation period. The highest cTnT values 
were observed in patients with a definite MI. Patients with a “raised cTnT only” had the highest 
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APACHE II score on admission, the highest proportion of patients with sepsis and also the highest IL-6 
results. (Table 2)  
 
At the time of peak cTnT levels, 71% patients had sepsis and 67% were on vasopressor treatment. 
Noradrenaline was the most frequently used vasopressor (89%).   
 
Association between troponin levels and inflammatory markers 
The medians for CRP, IL-6, PCT, NT-proBNP and cTnT were displayed for the 4 groups separately. 
(Figure 1) The graph illustrates the large variations of the different biomarkers between the 4 groups and 
the patterns of change within each group.  
Table 3 demonstrates the associations between cTnT and CRP, IL-6 and PCT and the presence of sepsis, 
both unadjusted and adjusted for potential confounders. Multivariable analysis showed an independent 
temporal association between cTnT and IL-6 in all patients with a cTnT rise. An increase in IL-6 by one 
SD was associated with a 16-23% rise in cTnT depending on individual cTnT group. In patients without a 
cTnT rise, there was no significant association between cTnT and IL-6.  
 
Cardiac troponin T was also independently associated with PCT levels in all patients except those with a 
definite MI. An increase in PCT by one SD was associated with a 13-17% rise in cTnT. 
 
There was an independent association between sepsis and cTnT results in patients with a definite MI and 
those with raised cTnT levels only. In cTnT positive patients without contemporaneous ECG changes, the 
mean cTnT levels were raised by 23% in patients with sepsis compared to those without sepsis. (Table 3). 
The adjusted estimates of percentage effect size and 95% CI, were displayed using a high low graph for 
the 4 groups. (Figure 2) 
 
Association between troponin levels and NT-proBNP 
There was a strong independent association between cTnT and NT-proBNP levels in all patient groups 
except those with a definite MI. (Table 3) An increase in NT-proBNP by one SD was associated with a 
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0.02% increase in cTnT. In patients without elevated cTnT levels, there was no associated NT-proBNP 
rise.  
 
DISCUSSION 
Our study confirmed an association between cTnT levels and markers of systemic inflammation and NT-
proBNP in critically ill patients admitted for non-cardiac reasons. In cTnT positive patients, there was a 
significant association between cTnT release and IL-6 levels independent of age, gender, renal function 
and presence of cardiovascular risk factors. An increase in IL-6 by one SD was associated with a 16-23% 
rise in cTnT. In addition, there was an independent association between cTnT levels and NT-proBNP in 
all patients except in those with a definite MI.  
 
These results support the current theories for troponin release in the absence of myocardial necrosis. A 
popular theory is that troponin release may be caused by cellular ischaemia without irreversible cell 
necrosis due to altered microcirculation (30, 31). Using isolated cultured myocardial cells, Schwartz et al 
showed that during limited periods of ischaemia, cultured cardiac myocytes remained viable but 
developed blebs containing cytoplasmic material (31). If ischaemia was corrected relatively quickly, the 
blebs were either reabsorbed or shed into the circulation without myocyte damage. In patients with septic 
shock, post-mortem examinations have also shown more pronounced histological abnormalities in 
troponin-positive patients compared to patients without a troponin rise (32).  
 
Ventricular dilatation and wall stress are other possible explanations for troponin release during sepsis. 
Studies in humans and animals suggest that cytokines, in particular IL-1β, IL-6 and tumour necrosis 
factor alpha (TNF-α) may play a role (33). TNF-α is known to increase the permeability of endothelial 
cells. Its effect on myocardial cells appears to be similar, thus leading to leakage of cTn (34). However, in 
healthy volunteers who underwent intravenous injection of endotoxin and subsequently developed 
significant elevations in serum TNF-α, IL-6, and IL-8 levels, there was no significant increase in systemic 
cTn levels which suggests that TNF-α alone may not be sufficient to induce significant changes (35). 
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In vitro studies have shown that serum obtained from patients with septic shock was able to depress rat 
cardiomyocytes’ contractility and induce ventricular dilatation (36, 37). Fernandes et al. described a 
correlation between raised troponin levels and left ventricular systolic dysfunction in critically ill patients 
with sepsis (38). Similarly, ver Elst et al showed that in patients with septic shock, elevated cTn levels 
were strongly associated with left ventricular dysfunction, as assessed by transoesophageal 
echocardiography (30). In a separate study of 37 patients with septic shock, those with raised troponin 
levels had a higher incidence of regional wall motion abnormalities on echocardiography (56% versus 
6%, p=0.002), lower ejection fraction (46% versus 62%, p=0.04) and higher mortality (56% versus 24%, 
p=0.04) compared to patients with normal troponin levels (39). Finally, Landesberg et al investigated 
general ICU patients with severe sepsis / septic shock and demonstrated that left ventricular diastolic 
dysfunction and right ventricular dilatation were the echocardiographic signs which correlated best with 
troponin elevation (40). 
 
Atrial and ventricular filling pressures in the left and right chambers are the main determinants of release 
of natriuretic peptides. NT-proBNP is a marker of ventricular dilatation and strain. In a sub-analysis of 
the Albumin Italian Outcome Sepsis trial including 995 patients with severe sepsis or septic shock, 
Masson et al showed that 97% of patients had NT-proBNP levels above the upper limit of normal and 
85% of patients had cTnT levels greater than normal (41). However, cardiac function was not directly 
assessed.  
 
Our findings support the hypothesis that troponin release during critical illness may be representative of 
both - systemic inflammation and ventricular strain. With serial troponin levels of 172 patients from 2 
different centers for up to 14 days, our study is one of the largest in the literature. The findings are 
strengthened by the fact that we a) only included ICU patients admitted for non-cardiac reasons, b) 
analysed patients in 4 different groups depending on whether they had a definite, possible or no MI 
during their stay in ICU, c) corrected for important confounding factors, d) had all ECGs interpreted 
independently by senior cardiologists who were blinded to the troponin results, and e) tested hypotheses 
which had been formed a priori.  
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It is still important to acknowledge some limitations. The observational nature of the study prevents us 
from defining causality between inflammatory markers and cTnT elevations. Second, we analysed 
patients with and without sepsis which may have impacted the strength of the associations. Third, we did 
not measure IL-1β or TNF-α, two key inflammatory cytokines. Similarly, we did not perform routine 
echocardiography in all patients to correlate the NT-proBNP results with ventricular dilatation and 
acknowledge that other mechanisms beyond ventricular stretch stimulate BNP release (42). Finally, we 
defined sepsis according to the previous consensus criteria as our study was conducted before the new 
sepsis criteria were published (27). 
 
Despite these limitations, we believe that our findings advance the understanding of troponin release 
during critical illness. Obviously, the results do not allow any recommendations regarding optimal 
management of troponin-positive patients after an MI has been excluded. We note the findings of a 
nationwide survey of 310 intensivists in the US regarding the management of ICU patients with elevated 
troponin levels without typical features of acute coronary syndrome (43). 76% of respondents stated that 
they would start either aspirin or clopidogrel, and 47% would commence heparin, 49% recommended 
high dose statins, 69% would start beta-blockers and 38% would use an angiotensin-converting-enzyme 
inhibitor. In addition, 73% of the intensivists would request a cardiology consultation and 52% would 
make a referral for coronary angiography. Given the wide variety of opinions, a better understanding and 
more guidance regarding the management of troponin-positive patients is urgently required.  
In conclusion, our results show that cTnT is associated with NT-pro-BNP and markers of systemic 
inflammation, especially in patients without a definite MI.  
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FIGURE LEGENDS 
 
Figure 1  Patterns of variations described by medians over time from Day 1 to Day 14 for the 
outcome cardiac troponin T and biomarkers of inflammation and ventricular strain in four groups 
 
The daily median values of CRP, IL-6, PCT, NT-proBNP and cTnT in their original units were 
graphically displayed to illustrate the variations of each biomarker over time in each of the 4 groups. NT-
proBNP was scaled down for the graph by dividing it by 100 to allow the presentation on the same scale 
as other parameters.  
 
Abbreviations: CRP = C-reactive protein; cTnT = cardiac troponin T; IL-6 = Interleukin-6; MI = 
myocardial infarction; NT-proBNP = N-terminal pro brain natriuretic peptide; PCT = procalcitonin 
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Figure 2  Adjusted percentage effect size and 95% Confidence Intervals for different biomarkers in 4 
groups  
Abbreviations: CRP = C-reactive protein; cTnT = cardiac troponin T; IL-6 = Interleukin 6; MI = 
myocardial infarction; UCI = Upper confidence interval; LCI = Lower confidence interval; NT-proBNP = 
N-terminal pro brain natriuretic peptide; PCT = procalcitonin 
Copyright © 2016 by the Shock Society. Unauthorized reproduction of this article is prohibited.
Copyright © 2016 by the Shock Society. Unauthorized reproduction of this article is prohibited.
Copyright © 2016 by the Shock Society. Unauthorized reproduction of this article is prohibited.
Table 1. Baseline characteristics of patients in the 4 groups 
Characteristics All groups Definite MI Possible MI Raised cTnT only No cTn rise P value *
Group size (n) 172 21 51 73 27  
Total number of cTnT 
results 
997 138 318 415 126  
Median number of cTnT 
results per patient (min - 
max) 
6 (1-11) 7 (1-11) 6 (1-11) 6 (1-11) 3 (1-11)  
        
Age, mean (SD) 63.0 (16.6) 61.4 (14.4) 68.6 (14.4) 64.9 (15.2) 48.4 (17.7) <0.01 
Female gender, n (%) 72 (42%) 8 (38%) 22 (43%) 34 (47%) 8 (30%) 0.48 
White ethnicity, n (%) 142 (83%) 18 (86%) 40 (80%) 63 (90%) 21 (84%) 0.33 
APACHE II score on 
admission to ICU, mean 
(SD) 
18.2 (6.6) 18.0 (6.22) 18.9 (6.2) 20.0 (6.5) 12.5 (4.8) <0.01 
Serum creatinine 
≥140µmol/L at any time 
during study period, n (%) 
76 (44.2%) 10 (47.6%) 26 (51%) 39 (53.4%) 1 (3.7%) <0.001 
Treatment with RRT, n 
(%) 54 (31.4%) 7 (33.3%) 16 (31.4%) 30 (41.1%) 1 (3.7%) 0.005 
RRT or serum creatinine 
≥140 µmol/L, n (%) 
87 (50.6%) 10 (47.6%) 31 (60.8%) 45(61.6%) 1 (3.7%) <0.001 
       
Comorbidities        
Ischaemic heart disease, n 
(%) 
33 (20%) 6 (29%) 12 (24%) 13 (18%) 2 (7%) 0.23 
Hypertension, n (%) 67 (39%) 8 (38%) 30 (59%) 24 (33%) 5 (19%) <0.01 
Diabetes, n (%) 51 (30%) 8 (38%) 20 (39%) 20 (27%) 3 (11%) 0.06 
Any form of vascular 
disease, n (%) 
34 (20%) 4 (19%) 15 (29%) 14 (19%) 1 (3.7%) 0.06 
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Abbreviations: APACHE = Acute Physiology and Chronic Health; cTnT = cardiac troponin T; ICU = intensive care unit; RRT = renal replacement therapy; SD = 
standard deviation 
 
 
* p-values are for the test of heterogeneity among the four proportions or means as appropriate
Mortality       
in hospital, n (%) 42 (24%) 6 (29%) 16 (31%) 19 (26%) 1 (3.7%) 0.03 
in ICU, n (%) 32 (19%) 5 (24%) 11 (22%) 15 (21%) 1 (3.7%) 0.44 
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 Table 2. Biomarkers of inflammation and ventricular dilatation in the 4 groups 
 
 Parameter Definite MI 
(n=21) 
Possible MI 
(n=51) 
Raised cTnT only 
(n=73) 
No cTnT rise 
(n=27) 
cTnT (ng/L)         
Mean (SD) 250.1 (477) 238.5 (486) 88.7 (143) 3.9 (4.1) 
Median 80.5 61 46 1.7 
IQR 171 150 82 4 
Range (min - max)  9 - 3093 5 - 3335 <0.3 - 1337 <0.3 – 14 
     
IL-6 (pg/mL)         
Mean (SD) 131.5 (323) 386.7 (1566) 1919 (20863) 142.0 (434) 
Median 48.1 55.8 55.1 51.8 
IQR 72 131.3 146.7 75.1 
Range (min - max)  <2 - 2522 <2 - 18120 <2 to >300000 5.49 – 4037 
     
CRP (mg/L)         
Mean (SD) 113.1 (78) 126.8 (86.5) 132.6 (97) 134.7 (84.3) 
Median 101.2 108.9 107.4 126.1 
IQR 125.1 113.8 144.2 125.3 
Range (min - max)  <4 - 448.3 <4 - 428.2 <4 - 499.1 <4 - 326.6 
     
PCT (ng/ml)         
Mean (SD) 4.1 (10.3) 6.3 (13.1) 8.2 (18.1) 2.3 (5.9) 
Median 0.7 1.5 2 0.4 
IQR 2.4 5.1 6.7 0.9 
Range (min - max)  0.1 - 75 0 - 75 0 - 199.5 0 - 41.3 
     
NT-pro-BNP  (ng/ml)     
Mean (SD) 15.8  (21.3) 15.1  (19.5) 7.27  (11.5) 1.97  (3.6) 
Median 6.6 7.4 3.0 0.3 
IQR 22.5 19.6 7.4 1.3 
Range (min - max)  0.02 - 155  0.08 - 108  0.02 – 75.5   0.02 – 16.5 
     
Sepsis* 15 (71%) 38 (75%) 57 (78%) 13 (48%) 
Any vasopressor use * 14 (67%)      37 (73%) 49 (67%) 10 (37%)   
Noradrenaline use * 13 (62%) 32 (63%)      44 (60%) 9 (33%) 
      
Abbreviations: CRP = C-reactive protein; cTnT = cardiac troponin T; IL-6 = Interleukin 6; MI = 
myocardial infarction; NT-pro-PNP = N-terminal pro brain natriuretic peptide; PCT = 
procalcitonin; SD = standard deviation; IQR = interquartile range.  
 
Values preceded by < indicate minimum level detected.  
Estimates presented in this table are based on all observations for all patients.  
 
* on day of peak cTnT level
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     Table 3. Unadjusted and adjusted estimates of associations of cTnT with sepsis and CRP, IL-l, PCT and NT-proBNP in different 
troponin groups 
 
Parameter 
Unadjusted estimates: 
Effect of factor on cTnT as a 
percentage per unit cTnT, except 
sepsis*  (95% CI) 
Adjusted estimates: 
Effect of factor on cTnT as a 
percentage per unit cTnT, except 
sepsis*  (95% CI) 
Standardised effect sizes for 
adjusted analysis equivalent to a 
SD change in the relevant marker 
Effect 
size (%) LCI UCI p-value 
Effect 
size (%) LCI UCI p-value
Effect 
size (%) LCI UCI 
Patients with definite MI (n=21) 
Sepsis  33 6.0 68 0.01 28.85 1.99 62.79 0.03    
CRP 0.13 -0.07 0.33 0.20 0.12 -0.08 0.32 0.25 9.70 -6.16 28.23 
IL-6 (log)**  N/A   0.006 N/A   0.02 23.37 3.68 46.80 
PCT 1.62 -0.06 3.33 0.06 1.30 -0.42 3.04 0.14 14.20 -4.21 36.15 
NT-proBNP   0.00 -0.0003 0.001 0.23 0.0004 -0.0004 0.0012 0.31 0.01 -0.01 0.02 
Patients with a possible MI (n=51) 
Sepsis 10.01 -5.48 28.03 0.22 5.98 -8.81 23.18 0.45    
CRP 0.13 0.03 0.23 0.01 0.11 0.01 0.21 0.03 10.08 0.85 20.16 
IL-6 (log)**  N/A   <0.001 N/A   <0.001 17.45 8.14 27.56 
PCT 1.32 0.36 2.29 0.007 1.20 0.25 2.15 0.01 16.86 3.31 32.17 
NT-proBNP   0.00 0.0006 0.001 <0.001 0.0010 0.0005 0.0015 <0.001 0.02 0.01 0.03 
Patients with raised cTnT only (n=73) 
Sepsis 22.12 6.56 39.95 0.004 23.17 4.99 37.80 0.01    
CRP 0.09 0.00 0.17 0.045 0.08 0.00 0.16 0.07 7.87 -0.47 16.92 
IL-6 (log)** N/A   0.001 N/A   <0.001 15.68 6.58 25.56 
PCT 0.68 0.30 1.07 <0.001 0.70 0.28 1.03 0.001 12.58 5.23 20.45 
NT-proBNP   0.00 0.0010 0.002 <0.001 0.0018 0.0006 0.0024 0.001 0.02 0.01 0.03 
Patients without raised cTnT (n=27) 
Sepsis -1.58 -15.80 15.03 0.84 -8.72 -21.03 5.51 0.22    
CRP 0.06 -0.03 0.15 0.16 0.00 -0.08 0.09 0.92 0.36 -6.35 7.55 
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 Continuation of Table 3: 
 
Abbreviations: CI = Confidence interval; CRP = C-reactive protein; cTnT = cardiac troponin T; IL-6 = Interleukin 
6; MI = myocardial infarction; UCI = Upper confidence interval; LCI = Lower confidence interval; NT-proBNP = 
N-terminal pro brain natriuretic peptide; PCT = procalcitonin; RRT = renal replacement therapy 
 
Adjusted mixed model gives average cTnT (outcome) after allowing for gender, age, ischaemic heart disease, 
hypertension, RRT use or creatinine ≥140 µmol/L, diabetes and any form of vascular disease. 
 
Use of standard effect sizes to estimate equivalent changes in cTnT:  
 
Examples: 
 
a) Relationship between cTnT and NT-proBNP:  The standardised effect size for NT-proBNP in patients with a 
definite MI is 0.01. To obtain the equivalent change in cTnT for a change in NT-proBNP, calculate the following: 
(value + 1) a    where value is the estimate as a proportion, and a is the change in NT-proBNP.  
For instance, the value of NT-proBNP is 0.01% (= 0.0001); to compute a 10 unit change, the formula translates 
into: (0.0001 + 1)10 = 1.001. This means, for a 10 unit change in NT-proBNP, the associated change of cTnT is 
0.001 (ie 0.1%). 
IL-6 (log)** N/A   0.31 N/A   0.31 -3.32 -9.45 3.24 
PCT 2.86 1.35 4.38 <0.001 2.21 0.89 3.54 0.001 13.74 5.35 22.79 
NT-proBNP   0.01 0.0036 0.008 <0.001 0.0049 0.0025 0.0073 <0.001 0.02 0.01 0.03 
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b) Impact of sepsis: The adjusted effect size describes the difference in cTnT between those with and without 
sepsis; eg if the value is 28.85%, the mean cTnT is raised by 28.85% in patients with sepsis compared to those 
without sepsis. 
*   Results are presented as the percentage change in cTnT as the inflammatory marker increases by one unit.  
 
** Since Il-6 was log transformed as well as cTnT, the ‘one-unit change’ estimates are not very meaningful and have been omitted 
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